InfuSystem Holdings Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole mounted and ambulatory infusion pumps; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. InfuSystem Holdings Inc. was founded in 2005 and is headquartered in Madison Heights, Michigan.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-248-2911210
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees237
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
InfuSystem (NYSEAMERICAN:INFU) Frequently Asked Questions
What is InfuSystem's stock symbol?
InfuSystem trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "INFU."
How will InfuSystem's stock buyback program work?
InfuSystem announced that its Board of Directors has authorized a stock buyback program on Tuesday, March 13th 2018, which authorizes the company to buyback 1,000,000 outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its shares are undervalued.
How were InfuSystem's earnings last quarter?
InfuSystem Holdings Inc (NYSEAMERICAN:INFU) released its quarterly earnings data on Wednesday, August, 14th. The medical instruments supplier reported $0.02 EPS for the quarter. The medical instruments supplier earned $19.72 million during the quarter. View InfuSystem's Earnings History.
When is InfuSystem's next earnings date?
Has InfuSystem been receiving favorable news coverage?
Media headlines about INFU stock have trended positive recently, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. InfuSystem earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for InfuSystem.
Are investors shorting InfuSystem?
InfuSystem saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 9,400 shares, a decline of 24.8% from the June 30th total of 12,500 shares. Based on an average trading volume of 15,900 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.1% of the shares of the company are sold short. View InfuSystem's Current Options Chain.
Who are some of InfuSystem's key competitors?
Some companies that are related to InfuSystem include Clover (CLV), CRH Medical (CRH), TransEnterix (TRXC), CRH Medical (CRHM), CRH Medical (CRHM), Bovie Medical (BVX), Bovie Medical (BVX), Tristel (TSTL), SDI (SDI), Impression Healthcare (IHL), G Medical (GMV), TSO3 (TOS), Daxor (DXR), IsoRay (ISR) and Retractable Technologies (RVP).
What other stocks do shareholders of InfuSystem own?
Who are InfuSystem's key executives?
InfuSystem's management team includes the folowing people:
- Mr. Richard A. DiIorio, Pres, CEO & Director (Age 44)
- Mr. Gregory Schulte, Exec. VP & CFO (Age 52)
- Mr. Thomas Mark Ruiz, Sr. VP of Sales & Marketing
- Mr. John Haggerty, Sr. VP of Biomedical Services & Logistics
- Ms. Jean Pfeiffer, Sr. VP of Strategic Initiatives
Who are InfuSystem's major shareholders?
InfuSystem's stock is owned by a variety of of retail and institutional investors. Top institutional investors include AWM Investment Company Inc. (9.42%) and White Pine Capital LLC (2.51%). Company insiders that own InfuSystem stock include Awm Investment Company, Inc, Christopher R Sansone, David C Dreyer, Gregg Owen Lehman, Meridian Ohc Partners, Lp, Richard Dilorio, Ronald H Jr Peele, Scott Shuda and Terry L Armstrong. View Institutional Ownership Trends for InfuSystem.
Which major investors are buying InfuSystem stock?
INFU stock was purchased by a variety of institutional investors in the last quarter, including AWM Investment Company Inc. and White Pine Capital LLC. Company insiders that have bought InfuSystem stock in the last two years include Awm Investment Company, Inc, Christopher R Sansone, Gregg Owen Lehman, Meridian Ohc Partners, Lp, Richard Dilorio, Ronald H Jr Peele, Scott Shuda and Terry L Armstrong. View Insider Buying and Selling for InfuSystem.
How do I buy shares of InfuSystem?
Shares of INFU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is InfuSystem's stock price today?
One share of INFU stock can currently be purchased for approximately $5.00.
How big of a company is InfuSystem?
What is InfuSystem's official website?
How can I contact InfuSystem?
InfuSystem's mailing address is 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States. The medical instruments supplier can be reached via phone at +1-248-2911210.
MarketBeat Community Rating for InfuSystem (NYSEAMERICAN INFU)
MarketBeat's community ratings are surveys of what our community members think about InfuSystem and other stocks. Vote "Outperform" if you believe INFU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFU will underperform the S&P 500 over the long term. You may vote once every thirty days.
